Fumarate ester dosage forms
Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.
1. A method of treating or reducing symptoms of a multiple sclerosis or psoriasis in a subject, the method comprising contacting peripheral blood mononuclear cells or monocytes of the subject with monomethyl fumarate by administering an oral pharmaceutical composition comprising one or more fumarate esters in an immediate releasing single phase non-aqueous liquid vehicle.
2. The method of claim 1 , wherein the fumarate ester comprises dimethyl fumarate, monomethyl fumarate, pro-drugs thereof, or combinations thereof.
3. The method of claim 1 , wherein the composition comprises about 80 mg to about 230 mg of the fumarate ester.
4. The method of claim 1 , wherein the liquid vehicle comprises mono- and di-glycerides, polyvinylpyrrolidone, and polyoxyl 40 hydrogenated castor oil.
5. The method of claim 1 , wherein the composition comprises:
about 30% to about 40% by weight of the one or more fumarate esters; and
about 55% to about 65% by weight of the liquid vehicle.
6. The method of claim 1 , wherein the composition comprises about 5% by weight of lactic acid.
7. The method of claim 1 , wherein the composition is encapsulated in a capsule.
8. The method of claim 1 , wherein the composition is encapsulated in a capsule comprising one or more subcoatings, enteric coatings, top coatings, or combinations thereof.
9. The method of claim 8 , wherein the capsule provides delayed release of the fumarate ester.
10. The method of claim 1 , wherein the subject is administered one or more units of the composition that cumulatively provide a daily dosage of a fumarate ester from about 160 mg to about 230 mg fumarate ester.
11. The method of claim 1 , wherein the subject is administered one or more units of the composition that cumulatively provide a daily dosage of a fumarate ester from about 320 mg to about 460 mg fumarate ester.
12. The method of claim 1 , wherein administration is twice per day.
13. The method of claim 1 , wherein two units of the composition comprising between about 80 mg to about 115 mg of fumarate ester are simultaneously administered twice per day.
14. The method of claim 1 , wherein 1 unit of the composition comprising between about 160 mg to about 230 mg of fumarate ester are administered twice per day.
15. The method of claim 1 , wherein upon administration to a subject, the composition activates a nuclear factor erythroid-derived 2-like (Nrf2) dependent pathway.
16. The method of claim 1 , wherein administering about 180 mg to about 200 mg of the fumarate ester is bioequivalent to administering a 240 mg dose of dimethyl fumarate.
17. A method of treating or reducing symptoms of multiple sclerosis or psoriasis in a subject, the method comprising contacting peripheral blood mononuclear cells or monocytes of the subject with monomethyl fumarate by administering an oral pharmaceutical composition comprising about 80 mg to about 230 mg of a prodrug of monomethyl fumarate, dimethyl fumarate, or monomethyl fumarate in an immediate releasing single phase non-aqueous liquid vehicle.
18. The method of claim 17 , wherein two units of the composition comprising between about 80 mg to about 115 mg of fumarate ester are simultaneously administered twice per day.
19. The method of claim 17 , wherein 1 unit of the composition comprising between about 160 mg to about 230 mg of fumarate ester are administered twice per day.
20. A method of activating a nuclear factor erythroid-derived 2-like (Nrf2) cellular signaling pathway in a subject, the method comprising contacting peripheral blood mononuclear cells or monocytes of the subject with monomethyl fumarate by administering an oral pharmaceutical composition comprising about 80 mg to about 230 mg of a prodrug of monomethyl fumarate, dimethyl fumarate, or monomethyl fumarate in an immediate releasing single phase non-aqueous liquid vehicle.